Search - tctmd.com

Displaying 1 - 20 of 33

Sort: Relevancy | Date

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Conference News ESC 2024

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

Todd Neale

September 09, 2024

News Daily News

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

Caitlin E. Cox

September 15, 2021

News Conference News

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

Shelley Wood

August 30, 2021

News Daily News

Periprocedural MIs Associated With PCI Prognostically Relevant: ESC/EAPCI

Michael O'Riordan

June 10, 2021

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

Caitlin E. Cox

May 24, 2021

News Daily News

Unplanned PCI Rare After TAVI, but Operators Get Good Results

Michael O'Riordan

January 18, 2021

News Conference News

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

Shelley Wood

November 19, 2020

News Conference News TCT 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

L.A. McKeown

October 22, 2020

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

Lancet COVID-19 Hydroxychloroquine Study Faces ‘Data Integrity’ Questions

News Daily News

TAVR Bests Surgical Redo for Failed Bioprostheses: Early Data

Michael O'Riordan

June 01, 2020

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Industry News

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

July 25, 2017

News Daily News

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Yael L. Maxwell

June 29, 2017

News Conference News EuroPCR 2017

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Michael O'Riordan

May 19, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

Advertisement

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

Periprocedural MIs Associated With PCI Prognostically Relevant: ESC/EAPCI

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

Unplanned PCI Rare After TAVI, but Operators Get Good Results

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

TAVR Bests Surgical Redo for Failed Bioprostheses: Early Data

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content